Abstract: MELF invasion has been associated with nonvaginal recurrences and lymph node (LN) metastases in multiinstitutional case control studies but has not been well examined in large single-institution cohorts. Hysterectomy specimens with FIGO 1 endometrioid endometrial carcinoma and lymphadenectomies from 2007 to 2012 were identified. Electronic medical records and histologic slides were reviewed. Of 464 identified cases, 163 (35.1%) were noninvasive, 60 (12.9%) had MELF, 222 (47.8%) had a component of the infiltrative invasion pattern without MELF, 13 (2.8%) had pure pushing borders of invasion, 5 (1.1%) had pure adenomyosis-like invasion, and 1 (0.2%) had pure adenoma malignum-like invasion. Sixteen cases had LN metastases. Significantly more MELF cases had positive LNs than non-MELF cases overall (18.3% vs. 1.2%, P < 0.001). The results were almost identical when invasive infiltrative cases with and without MELF were compared (18.3% vs. 1.8%, P < 0.001). The maximum number of MELF glands per slide did not differ between cases with and without LN metastases, P = 0.137. A majority of positive LNs, even in MELF cases, demonstrated nonhistiocyte-like metastases. Only 5 cases (all with MELF invasion) demonstrated micrometastatic lesions or isolated tumor cells only. MELF cases demonstrated a nonsignificant decrease in time to extravaginal recurrence (P = 0.082, log-rank test), for which analysis was limited by low recurrence rates. In summary, MELF is associated with LN metastases, even when compared with other infiltrative cases and shows multiple patterns of growth in positive LNs. MELF cases additionally trended toward decreased time to extravaginal recurrence.
M
ost FIGO grade 1 endometrioid endometrial carcinomas (EEC) present with early-stage disease and have an excellent prognosis. [1] [2] [3] However, a minority with early-stage, low-grade disease will demonstrate a more aggressive clinical course. A priori identification of such cases could allow offering additional treatment to women who may benefit the most. 4 EECs are histologically heterogenous, and the morphologic pattern of myometrial invasion may be related to biological potential. 5, 6 Specifically, myometrial invasion with an infiltrative gland pattern has been recently associated with higher stage, lymphovascular invasion, and recurrence. 6 In addition, a readily recognizable pattern of myometrial invasion characterized by microcystic, elongated, and fragmented (MELF) glands surrounded by myxoid and inflamed stroma has been associated with lymphovascular invasion 7, 8 and lymph node (LN) metastases. 7, [9] [10] [11] This morphologic pattern was initially recognized by Lee et al, 12 and the term MELF was later coined by Murray et al. 13 Immunophenotypic changes including loss or reduction of CD147, MMP2, 14 e-cadherin, 10 and Galectin-3 15 may indicate epithelial mesenchymal transition (EMT) in MELF. EMT, which results in loss of cell-cell adhesion and polarity, endows cells with migratory and invasive properties. 16 EMT has been associated with poor prognostic parameters in breast, colorectal, and ovarian cancers. 16 Herein, we investigate the clinical and pathologic associations of MELF in FIGO grade 1 EEC, including LN metastases and vaginal and nonvaginal recurrences. By analyzing a large number of consecutive unselected single-institution grade 1 EECs we avoid case selection bias inherent in case-control designs. By excluding the clinically more variable and pathologically less reproducible FIGO grade 2 EEC, we seek to clarify the implications of MELF in women for whom it would matter the most: those in whom the standard of care may most frequently include forgoing adjuvant therapy. We report on the influence of MELF on grade 1 EEC overall as well as within grade 1 EEC, which features infiltrative invasion already thought to be associated with worse outcomes. In addition, we describe the pathologic features of MELFassociated LN metastases, which has been the subject of very scant and occasionally incomplete reports. 5 were utilized to classify each invasive case: irregular or infiltrative invasion, MELF invasion, invasion with pushing borders (broad front), adenomyosis-like invasion, and adenoma malignum-like invasion. For cases with multiple patterns of invasion, each pattern and its relative proportion was recorded. If MELF pattern of invasion was present, a single gynecologic pathologist (A.A.S.) selected the slide with the heaviest MELF burden. The slide was then reviewed by a second gynecologic pathologist (D.W.C.) for confirmation and to count the number of MELF glands on that single slide. Intermixed cases without MELF were also given to the second gynecologic pathologist for quality assurance purposes, and in cases with disagreement as to the presence of MELF, joint review and consensus was attained.
MATERIALS AND METHODS

Under
Fisher exact tests (2-tailed) were used to compare proportions of cases with LN metastases between MELF and non-MELF cases overall, and between MELF cases and the subset of infiltrative non-MELF cases. A Wilcoxon rank sum test was used to compare the number of MELF glands per slide with the presence or absence of LN metastases. Median time to nonvaginal recurrence was planned using Kaplan-Meier estimates. The KaplanMeier curves for MELF and non-MELF were compared using a log-rank test. Time to recurrence was defined as the time from surgery date to first recurrence. For the recurrence analysis, patients were censored if they were alive without disease at the time of last follow-up visit, were disease-free but died of other causes, or if no outcome data were available. All statistical analyses were performed using Stata 13 (Statacorp LP, College Station, TX) or SAS 9.3 (SAS Institute Inc., Cary, NC).
Positive LN slides were reviewed for histologic patterns of metastases and to measure the diameter of largest metastasis in each case. Unless it was performed for clinical or pathologic suspicion at the time of the original case, no cytokeratin immunostains were used to routinely identify micrometastases or isolated tumor cells in LN sections. Confirmation of several measurements, including all micrometastatic cases, was performed by a breast pathologist (Z.L.) according to standard breast definitions. 17 
RESULTS
A total of 464 consecutive hysterectomy specimens with FIGO 1 EEC and accompanying lymphadenectomies were identified and pulled for review. There were 163 (35.1%) noninvasive tumors and 301 (64.9%) myoinvasive tumors. Sixty-eight cases were initially identified as demonstrating MELF. After review of these cases plus controls by a second pathologist, 14 cases required consensus microscopic review as to the presence of MELF (13 potential MELF cases, 1 negative control). Of these cases, 5 remained in the MELF group, and the other 9 were included in the infiltrative (n = 8) or noninvasive (n = 1) categories detailed above. Ultimately, 60 tumors (12.9%) were identified as having a component of MELF ( Fig. 1 ). One case with 12 MELF glands in the slide with the heaviest burden showed pure MELF pattern invasion, whereas all of the remaining 59 cases showed overlap with the infiltrative or irregular invasion pattern. Of the remaining myoinvasive tumors, 222 (47.8%) had a component of infiltrative or irregular invasion pattern without MELF, 13 (2.8%) had pure pushing borders of invasion, 5 (1.1%) had pure adenomyosis-like invasion, and 1 (0.2%) showed adenoma malignum-like invasion. No cases of pushing borders, adenomyosis-like invasion, or adenoma malignum-like invasion showed any component of MELF pattern invasion. In the MELF cases, 1 to 17 (median = 2) MELF glands were identified on the glass slide with the highest count of MELF glands in each case.
LN Involvement
LN metastases were found in 16 cases (3.4%). The clinicopathologic details of these cases are outlined in Table 1 . The proportion of MELF cases with positive LNs was significantly higher than the proportion of non-MELF cases (18.3% vs. 1.2%, P < 0.001, Fisher exact test). A similar difference was found in a subset of cases (n = 282) comparing the MELF cases with infiltrative invasive cases without MELF (18.3% vs. 1.8%, P < 0.001, Fisher exact test). Although the number of MELF glands per slide was higher in cases with LN metastases than in cases without LN metastases, the difference was not statistically significant (average 5.82 vs. 3.41 glands, P = 0.137, Wilcoxon rank sum test). Additional variables, such as pT stage, could not be controlled for in a multivariable analysis due to the overall low rate of LN involvement.
Review of positive LN slides demonstrated multiple histologic patterns. Metastases were grouped into 3 categories: sinus histiocyte-like, solid and glandular, and cystic glandular (Fig. 2) . Multiple patterns were observed in separate LNs of the same case, as well as in different areas or sections of the same LN. Of the 11 MELF cases with positive LNs, 5 showed sinus histiocyte-like metastases, 5 had solid glandular metastases, and 5 had cystic glandular metastases. In the 5 non-MELF cases with positive LNs, 2 showed sinus histiocyte-like metastases, 4 showed solid glandular metastases, and 2 showed cystic glandular metastases. Five cases had only low-volume LN metastases including isolated tumor cells and micrometastases (cases 109, 110, 206, 253, and 444; Table 1 ). Low-volume LN metastases, including isolated tumor cells and micrometastases, were only seen in cases with MELF. Interestingly, not all of these low volume metastases were of the sinus-histiocyte like pattern. However, the remaining MELF cases had larger nodal metastases overlapping with those of non-MELF tumors.
Recurrence and Other Adverse Outcomes
Patients had a median of 35 months of follow-up, ranging from <1 month to 90 months. Twenty (4.3%) patients developed recurrent disease over a range of 5 to 53 months, of which 9 (45.0%) had an isolated vaginal recurrence and 11 (55.0%) had extravaginal recurrence. Clinicopathologic details of all patients with recurrences are outlined in Table 2 . Of note, no patients with the MELF pattern of invasion experienced vaginal-only recurrences. In addition, no recurrences occurred in patients who demonstrated LNs with isolated tumor cells or micrometastases only. Extravaginal recurrences occurred in 3 (5.0%) MELF cases (at 8, 10, and 47 mo follow-up time) and in 9 (2.0%) non-MELF cases (at 5 to 53 mo follow-up time). Kaplan-Meier curves were constructed, and no significant difference in nonvaginal recurrence was found between MELF and non-MELF cases, P = 0.082 (log-rank test). The median time to recurrence could not be estimated due to the low absolute number of events. A subgroup analysis comparing the MELF cases (n = 60) and non-MELF infiltrative/irregular invasion patterns only (n = 222), in which 7 nonvaginal recurrences occurred, similarly showed no statistically significant difference, P = 0.392 (log-rank test).
The univariate Cox proportional hazards model showed no significant difference in rate of nonvaginal recurrences in MELF versus non-MELF cases (hazard ratio = 3.06, P = 0.099). Further analysis using a multivariable Cox proportional hazards model was not possible due to the small absolute number of recurrences in the cohort. In addition, too Other adverse outcomes noted in the cohort included 5 (1.1%) patients who died of disease, 12 (2.6%) patients who died of other known causes, and 9 (1.9%) patients who died of unknown causes. As detailed in Table 2 , 6 patients with recurrences were alive with disease at the time of submission, after varying follow-up periods (range 5 to 53 mo). Although treatment variables are not a component of our analysis, it is of note that 9 of 11 patients with extravaginal recurrence received chemotherapy with or without radiation therapy, with the 2 remaining patients receiving hormonal therapy (tamoxifen, megestrol) or not returning to follow-up appointments, respectively. Among the 9 vaginal recurrences, 4 patients received a combination of chemotherapy and radiation therapy, 3 received radiation therapy alone, and 1 received radiation and hormonal therapies. One patient did not return for follow-up appointments. Of the patients with positive LNs, 13 of 16 patients received chemotherapy with or without radiation therapy. Information about clinical follow-up and adjuvant treatments was not available on the remaining 3 patients, as their care was transferred back to referring oncologists.
DISCUSSION
We studied LN metastases and nonvaginal recurrences among 464 single-institution, consecutive cases of FIGO grade 1 EEC, for which patients underwent hysterectomy with staging lymphadenectomies. We confirmed previous reports that patients whose tumors demonstrated MELF invasion have an increased propensity to also demonstrate LN metastases. We also demonstrated that this association between MELF and LN metastases remained significant when only myoinvasive tumors with an irregular, infiltrative pattern and no MELF (n = 222) were compared with MELF cases (n = 60) (1.8% vs. 18.3%, P < 0.001, Fisher exact test).
Several investigators have studied the MELF pattern of invasion in relation to LN metastases. In fact, a case of pT1a grade 1 EEC with positive LNs was reported by Clement and Young 18 along with an early description of this pattern of myometrial invasion before the term MELF had even been coined. McKenney et al 19 followed with a report of well-differentiated endometrioid carcinomas with positive LNs including 2 cases with MELF.
More recently, a few larger series have been published trying to clarify MELF associations with lymphovascular invasion 7, 8 and LN metastases. 7,9-11, 20 Stewart et al 8 and Hertel et al 7 reported strong associations with lymphovascular invasion. Pavlakis et al, 9 Han et al, 10 Hertel et al, 7 and Dogan Altunpulluk et al 11 reported LN metastases in 54%, 67%, 67% to 100%, and 71% of their respective cases, whereas Euscher et al 20 reported MELF in 70% of their tumors with LN metastases or extrauterine disease. However, putting these high percentages into perspective and comparing these series is a nuanced exercise due to varying methods and case selection. Han et al 10 in their study of 18 stage 1 FIGO grade 1 endometrioid carcinomas with "occult" LN metastases and 36 controls reported MELF to be univariately but not multivariately associated with LN metastases. Hertel et al 7 studied 80 pT1 low-grade endometrioid adenocarcinomas with lymphovascular invasion and documented higher rates of nodal metastasis among those with MELF. Interestingly, Hertel et al 7 also reported that the amount of MELF correlated with the rate of LN metastases, whereas in our current study there was no association of MELF glands per slide with LN metastases. Dogan Altunpulluk et al 11 reported MELF in 28 (including 8 FIGO grade 3 tumors) of 121 consecutive hysterectomies with endometrial cancer and documented an association with LN metastases on univariate and multivariate analyses. However, FIGO grading and clinical stage were not included in the multivariable model, despite significant associations of these variables with LN metastases and presence of MELF. 11 Finally, a multiinstitution case-control study of 304 tumors by Euscher et al 20 showed MELF as a univariate but not multivariate predictor of LN metastases or extrauterine disease. However, the large proportion of FIGO grade 2 cases in the latter study may reflect selection bias by more lymphadenectomies being performed in higher-grade cases. 20 Some investigators have reported on the size 10 and histologic features 7, [9] [10] 20 of LN metastases in carcinomas with MELF. Subtle sinus histiocyte-like morphology has been emphasized 7, 10 with one institution even reporting it as the sole pattern of LN metastasis. 9 The use of cytokeratin immunostains in otherwise negative LNs may have contributed very significantly to these data. 7, 9, 10 We did find sinus histiocyte-like deposits as the sole morphologic pattern in 4 of 11 MELF cases with positive nodes. However, other patterns were seen in the majority. Han et al, 10 using terminology better validated in the breast cancer LN literature, reported "isolated tumor cells only" in 12 of their cases with MELF and positive nodes. In our study, we found LN metastases measuring <2 mm (n = 5) only among cases with MELF. Of note, 4 of these patients were alive with no evidence of disease at their last follow-up. Last follow-up visit was at 3 and 5 years for 2 of the patients; unfortunately it was limited to their last visit for chemotherapy in the other 2. These 4 patients had received standard 6-cycle chemotherapy regimens with carboplatin and paclitaxel, and 2 of them had bevacizumab as part of a clinical trial. No treatment details or follow-up information were available on 1 of the patients with metastases <2 mm. Six of 11 cases with MELF had larger metastases, up to 16 mm. Although it is becoming increasingly prevalent in the endometrial cancer literature and has been included in the current College of American Pathologists endometrial cancer checklist, 21 the breast cancer constructs of "isolated tumor cells" and "micrometastasis" should probably be used with caution in endometrial cancer. Currently, there is limited and conflicting evidence as to whether micrometastases are clinically significant in various stages and grades of endometrial adenocarcinoma, [22] [23] [24] [25] with additional larger and long-term studies required. Thus, whether additional therapy may benefit women with low-grade EEC, MELF, and LN tumor deposits within these size ranges (micrometastases, isolated tumor cells) is a pressing matter.
Thus, we contribute data to dispel the impression that LN metastases in low-grade endometrial carcinomas with MELF are mostly small and subtle. The significant association of MELF with LN metastases is important, especially as lymphadenectomy may not be performed in all patients with grade 1 EEC by biopsy. Reporting MELF in hysterectomy specimens with EEC may aid treating oncologists in deciding further therapy or completion lymphadenectomy when lymphadenectomy is not performed concurrent with the hysterectomy. Similarly, the possibility of reporting MELF on frozen sections to influence an intraoperative decision regarding lymphadenectomy may be worth exploring.
In the present study of consecutive cases, there were no statistically significant differences between cases with and without MELF in extravaginal recurrences, but this analysis is limited by the low number of events: 3 and 9 recurrences, respectively. MELF was identified in 53% of tumors that led to extravaginal recurrences compared with 30% in vaginal recurrences and 33% in cases without recurrence in a retrospective multi-institutional study. 26 Although the association was statistically significant in that study, the case-control design with many FIGO grade 2 tumors is of note. 26 Our strengths include a large number of consecutive patients with accompanying lymphadenectomies. In addition, the inclusion of only FIGO grade 1 tumors focuses the analysis on those tumors for which, other variables being equal, an indolent behavior is most reasonably expected. Therefore, we have optimized the study to detect and isolate a negative impact of MELF on the variables reported while also avoiding the weaknesses of casecontrol designs and maximizing the potential clinical impact of MELF. This was done at the expense of having lower counts (16 cases with positive nodes, 5 dead of disease, 6 alive with disease) than could otherwise easily be obtained at our institution. 2 As a result, our analysis of nonvaginal recurrences and other adverse outcomes is very limited, without thorough multivariable conclusions. Moreover, a majority (13/16) of patients with positive nodes received adjuvant chemotherapy and/or radiotherapy, complicating extrapolation of our findings to women who may have had only hysterectomy and for whom additional therapy is being considered. However, the relative rarity of adverse outcomes is a main difficulty faced by all research attempting to identify those grade 1 EECs that will go on to behave more aggressively.
We conclude that women with FIGO grade 1 EEC and MELF are at a significantly increased risk of regional LN metastases. This justifies the inclusion of this finding in pathology reports, especially in women who have not had staging lymphadenectomies. Although molecular data are increasingly incorporated into clinical thinking and practice, 27, 28 histologic findings, including MELF, will continue to provide a main framework for pathology reports. It is important to put them into a clear and clinically useful perspective.
